Hakutulokset - Brendon L. Neuen
- Näytetään 1 - 20 yhteensä 49 tuloksesta
- Siirry seuraavalle sivulle
-
1
-
2
Empagliflozin in Patients with Chronic Kidney Disease Tekijä Brendon L. Neuen, Robert A. Fletcher, Hiddo J.L. Heerspink
Julkaistu 2023Carta -
3
Chronic kidney disease and the global NCDs agenda Tekijä Brendon L. Neuen, Steven J. Chadban, Alessandro Demaio, David W. Johnson, Vlado Perkovic
Julkaistu 2017Editorial -
4
Chronic kidney disease Tekijä Kamyar Kalantar‐Zadeh, Tazeen H. Jafar, Dorothea Nitsch, Brendon L. Neuen, Vlado Perkovic
Julkaistu 2021Revisão -
5
-
6
-
7
-
8
-
9
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes Tekijä Jingwei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L. Neuen, Clare Arnott, Robin Simpson, Richard Oh, Kenneth W. Mahaffey, Hiddo J.L. Heerspink
Julkaistu 2020Artigo -
10
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis... Tekijä Tadashi Toyama, Brendon L. Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg Jardine, Hiddo J.L. Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada, Vlado Perkovic
Julkaistu 2019Revisão -
11
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials Tekijä Sheldon W. Tobe, Thomas A. Mavrakanas, Harpreet S. Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L. Neuen, Vlado Perkovic, Kenneth W. Mahaffey, Wally Rapattoni, Fernando G. Ang
Julkaistu 2024Artigo -
12
Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis Tekijä Clare Arnott, Qiang Li, Amy Kang, Brendon L. Neuen, Séverine Bompoint, Carolyn S.P. Lam, Anthony Rodgers, Kenneth W. Mahaffey, Christopher P. Cannon, Vlado Perkovic, Meg Jardine, Bruce Neal
Julkaistu 2020Revisão -
13
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial Tekijä Jennifer Barraclough, Jie Yu, Gemma A. Figtree, Vlado Perkovic, Hiddo J.L. Heerspink, Brendon L. Neuen, Christopher P. Cannon, Kenneth W. Mahaffey, Aletta E. Schutte, Bruce Neal, Clare Arnott
Julkaistu 2022Artigo -
14
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the D... Tekijä Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol A. Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink
Julkaistu 2023Artigo -
15
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program Tekijä Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh, Hiddo J.L. Heerspink, Vlado Perkovic
Julkaistu 2019Artigo -
16
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program Tekijä Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Jaime D. Blais, Qiang Li, Meg Jardine, Vlado Perkovic, David C. Wheeler
Julkaistu 2020Artigo -
17
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS Tekijä Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L. Neuen, Bruce Neal, Clare Arnott, Vlado Perkovic, Paul M. Ridker, Katherine R. Tuttle, Michael K. Hansen, Hiddo J.L. Heerspink
Julkaistu 2022Artigo -
18
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis Tekijä Brendon L. Neuen, Robert A. Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil V. Badve, Katherine R. Tuttle, Richard E. Pratley, Hertzel C. Gerstein, Vlado Perkovic, Hiddo J.L. Heerspink
Julkaistu 2024Revisão -
19
The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial Tekijä Clare Arnott, Yuli Huang, Brendon L. Neuen, Gian Luca Di Tanna, Christopher P. Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey, Bruce Neal
Julkaistu 2020Artigo -
20
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis Tekijä Brendon L. Neuen, T. Kue Young, Hiddo J.L. Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W. Mahaffey, David M. Charytan, David C. Wheeler, Clare Arnott, Séverine Bompoint, Adeera Levin, Meg Jardine
Julkaistu 2019Revisão
Työkalut:
Liittyvät aiheet
Internal medicine
Medicine
Endocrinology
Kidney disease
Diabetes mellitus
Type 2 diabetes
Pathology
Renal function
Canagliflozin
Intensive care medicine
Confidence interval
Alternative medicine
Hazard ratio
Placebo
Albuminuria
Environmental health
Meta-analysis
Disease
Kidney
Empagliflozin
Pharmacology
Population
Proportional hazards model
Randomized controlled trial
Urology
Adverse effect
Cardiology
Chemistry
Creatinine
Post-hoc analysis